NIMG-26. DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET

BACKGROUND: The CeTeG/NOA-09 trial demonstrated a significant survival benefit of radiotherapy plus lomustine-temozolomide chemotherapy in glioblastoma patients with methylated O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter compared to standard temozolomide chemoradiation (1). However, dat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Principais autores: Werner, Jan-Michael, Ceccon, Garry, Weller, Johannes, Schaub, Christina, Tscherpel, Caroline, Lohmann, Philipp, Bauer, Elena, Schäfer, Niklas, Stoffels, Gabriele, Kabbasch, Christoph, Baues, Christian, Marnitz, Simone, Fink, Gereon R, Langen, Karl-Josef, Herrlinger, Ulrich, Galldiks, Norbert
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Neuroimaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651124/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.639
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados